Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
We send one confirmation email first. Only emails about RVMD, unsubscribe in one click. Privacy
Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.
Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.
| Drug | Indication | Most advanced trial | Status |
|---|---|---|---|
| Daraxonrasib (RMC-6236) FDA approved Aug 2026 · Rasonque |
Pancreatic Cancer | Phase 3 · NCT06625320 | Active not recruiting |
| Zoldonrasib (RMC-9805) | NSCLC | Phase 3 · NCT07777822 | Recruiting |
| Nab-paclitaxel | Pancreatic Cancer | Phase 3 · NCT06625320 | Active not recruiting |
| Liposomal irinotecan | Pancreatic Cancer | Phase 3 · NCT06625320 | Active not recruiting |
| Fluorouracil | Pancreatic Cancer | Phase 3 · NCT06625320 | Active not recruiting |
| Irinotecan | Pancreatic Cancer | Phase 3 · NCT06625320 | Active not recruiting |
| Vociprotafib (RMC-4630) | Metastatic Neoplasm | Phase 1/2 · NCT04418661 | Terminated |
| Vopimetostat (TNG462) | PDAC | Phase 1/2 · NCT06922591 | Recruiting |
| Elironrasib (RMC-6291) | Non-Small Cell Lung Cancer, NSCLC | Phase 1/2 · NCT06162221 | Recruiting |
| mFOLFIRINOX regimen | Colorectal Cancer | Phase 1/2 · NCT06445062 | Recruiting |
| Osimertinib Mesylate | Solid Tumor | Phase 1/2 · NCT03989115 | Completed |
| FOLFIRI regimen | Colorectal Cancer | Phase 1/2 · NCT06445062 | Recruiting |
| Ivonescimab | Advanced Solid Tumors | Phase 1/2 · NCT07397338 | Recruiting |
| mFOLFIRINOX | PDAC | Phase 1/2 · NCT06922591 | Recruiting |
| mFOLFOX6 regimen | Colorectal Cancer | Phase 1/2 · NCT06445062 | Recruiting |
| KRAS G12V Inhibitor RMC-5127 | Non-small Cell Lung Cancer (NSCLC) | Phase 1 · NCT07349537 | Recruiting |
Also used in these trials (approved or third-party drugs, not RVMD's own candidates): Leucovorin, Pemetrexed Disodium, Pembrolizumab, Oxaliplatin, Gemcitabine Hydrochloride, Docetaxel Anhydrous, Carboplatin, Adagrasib, Sotorasib, Bevacizumab, Cobimetinib, Cisplatin.
Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it
RVMD holds $4.2B in cash and short-term investments (as of Sep 30, 2026) and burns about $401.5M/quarter from operations, an estimated runway of 31.3 months at that rate (BioRadar estimate, not company guidance).
Dilution pressure: 32 · Moderate
Recent financing filings on SEC EDGAR:
Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when RVMD files for a raise →
| Holder | Type | Shares | % of shares | As of |
|---|---|---|---|---|
| FMR LLC | Institution (13G, 5%+) | 15,402,103 | 7.12% | 2026-09-30 |
| Dapice Joshua J. | 5%+ holder (13G) | 14,596,149 | 6.75% | 2025-12-31 |
| Farallon Capital Management, L.L.C. | Institution (13G, 5%+) | 13,564,149 | 6.27% | 2026-06-30 |
| Farallon Capital Management LLC | Institution (13F) | 13,418,796 | 6.20% | 2026-09-30 |
| BlackRock, Inc. | Institution (13G, 5%+) | 12,201,395 | 5.64% | 2026-06-30 |
| Baker Bros. Advisors LP | Institution (13G, 5%+) | 11,443,357 | 5.29% | 2026-06-30 |
| Vanguard Capital Management | Institution (13G, 5%+) | 10,999,044 | 5.09% | 2026-09-30 |
| JANUS HENDERSON GROUP Ltd. | Institution (13G, 5%+) | 10,736,145 | 4.96% | 2026-06-30 |
| Darwin Global Management, Ltd. | Institution (13F) | 10,629,822 | 4.91% | 2026-09-30 |
| Vanguard Portfolio Management LLC | Institution (13F) | 8,157,073 | 3.77% | 2026-09-30 |
| Nextech Invest, Ltd. | Institution (13F) | 7,601,087 | 3.51% | 2026-09-30 |
| Paradigm Biocapital Advisors LP | Institution (13F) | 6,219,323 | 2.88% | 2026-09-30 |
Share count 216,292,323 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest (13F quarter ending 2026-09-30). Sources have different dates, so the split is approximate. Source: SEC EDGAR.
| Trade date | Insider | Transaction | Shares | Price | Owned after |
|---|---|---|---|---|---|
| 2026-11-11 filed 2026-11-13 |
Borisy Alexis |
Gift (G) | 10,625 | – | 2,329,450 |
| 2026-11-11 filed 2026-11-13 |
Anders Jack |
Option exercise (M) | 19,850 | $18.56 | – |
| 2026-11-11 filed 2026-11-13 |
Anders Jack |
Option exercise (M) | 15,900 | $42.45 | – |
| 2026-11-11 filed 2026-11-13 |
Anders Jack |
Sale (S) | 9,889 | $192.84 | 119,216 |
| 2026-11-11 filed 2026-11-13 |
Anders Jack |
Sale (S) | 9,486 | $191.94 | 129,105 |
Only open-market purchases (P) and sales (S) are trading decisions. Awards (A), option exercises (M) and tax withholding (F) are compensation mechanics. Source: SEC Form 4.
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for RVMD and every other ticker you follow. Card required, cancel anytime.
Start 7-day free trial →